Heart failure is still one of the most common and costly hospitalizations in the United States. The goal is to enable patients, who survive a myocardial infarction, to live longer by limiting the effects of damaged myocardium. Scientific and clinical attention has focused on regenerative medicine, which uses stem cell therapies and cardiac ablation to correct heart rhythm disorders. This has fueled research on new advanced intramyocardial delivery devices. They are useful for the direct administration into the myocardium, via injection in open-chest procedures, of various drug compounds, an action that requires certain methods of mixing, administration, precision, timing, and monitoring.